Genuity

NetWitness Incident Response Team Urges Enterprises to Prepare for Potential Cyberattacks Related to Russia/Ukraine Conflict

Retrieved on: 
Thursday, March 24, 2022
Networks, Internet, Security, Technology, Software, Social policy of the Joe Biden administration, Face, CISSP, Organization, Cybereason, United States Department of Justice, Netwitness, Department of Defense Cyber Crime Center, BBN, RSA, Administration, Intelligence, United States Department of Defense, Incident, State Street Corporation, Justice, Digital, IR, AltaVista, Risk management, Defense, Genuity

NetWitness , an RSA business, and globally trusted provider of cybersecurity technologies and incident response services, today released guidance from its Incident Response team urging global enterprises to take measures to prepare for potential cyberattacks related to the ongoing conflict between Russia and Ukraine.

Key Points: 
  • NetWitness , an RSA business, and globally trusted provider of cybersecurity technologies and incident response services, today released guidance from its Incident Response team urging global enterprises to take measures to prepare for potential cyberattacks related to the ongoing conflict between Russia and Ukraine.
  • The NetWitness Incident Response team is available to assist organizations with enacting these recommendations, as well as several other services, and does not require organizations to be existing NetWitness customers or have NetWitness technology in place.
  • These services include:
    Incident Response Retainer: The NetWitness IR team stands by to help mitigate the impact of an incident through proactive response, leveraging the NetWitness Platform and third-party solutions already in use by the customer.
  • Incident Response Rapid Deploy: The IR team mobilizes following a breach to minimize damage and gather intelligence using NetWitness solutions.

Proactive Group Holdings enters strategic alliance with Canaccord Genuity Group Inc

Retrieved on: 
Monday, October 25, 2021
Research, CG, Canaccord Genuity, Genuity, Solution, GLOBE, Public relations, Financial services

Toronto , Oct. 25, 2021 (GLOBE NEWSWIRE) -- Toronto, October 25, 2021 (GLOBE NEWSWIRE) Proactive Group Holdings (Proactive) is pleased to announce it has entered into a strategic alliance agreement (the agreement) with Canaccord Genuity Group, Inc. (Canaccord Genuity or CG).

Key Points: 
  • Toronto , Oct. 25, 2021 (GLOBE NEWSWIRE) -- Toronto, October 25, 2021 (GLOBE NEWSWIRE) Proactive Group Holdings (Proactive) is pleased to announce it has entered into a strategic alliance agreement (the agreement) with Canaccord Genuity Group, Inc. (Canaccord Genuity or CG).
  • As part of the agreement, Canaccord Genuity will make a direct investment in Proactive.
  • Proactive CEO Ian Mclelland said: This strategic alliance agreement and investment from Canaccord Genuity provides a very strong endorsement of Proactives ability to provide meaningful value to growth companies.
  • Canaccord Genuity has worked with thousands of growth companies worldwide and understands the merits of a robust investor engagement strategy.

Boxed to Participate in the Canaccord Genuity 41st Annual Growth Conference

Retrieved on: 
Wednesday, August 4, 2021
Canaccord Genuity, Service companies, Genuity, E-commerce, Boxed.com, Distribution marketing), Industry economics)

NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Boxed, an e-commerce grocery platform selling bulk consumables to households and businesses, and an e-commerce enabler selling software and services to enterprise retailers around the world, announced today that Boxed is participating in the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021.

Key Points: 
  • NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Boxed, an e-commerce grocery platform selling bulk consumables to households and businesses, and an e-commerce enabler selling software and services to enterprise retailers around the world, announced today that Boxed is participating in the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021.
  • Boxed further enables e-commerce through its Software & Services business, which offers customers in need of an enterprise-level e-commerce platform access to its end-to-end technology.
  • Seven Oaks Acquisition Corp. is a special purpose acquisition company formed for the purpose of entering into a business combination.
  • Neither Seven Oaks nor Boxed undertakes any duty to update these forward-looking statements.

X4 Pharmaceuticals to Participate at Canaccord Genuity’s Virtual 41st Annual Growth Conference

Retrieved on: 
Wednesday, August 4, 2021
Chemokine receptors, Branches of biology, CXCR4, Canaccord Genuity, CXC chemokine receptors, Genuity, HIV, Chemokine

BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, today announced that management will participate in a fireside chat at Canaccord Genuitys 41st Annual Growth Conference on Thursday, August 12, 2021.

Key Points: 
  • BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, today announced that management will participate in a fireside chat at Canaccord Genuitys 41st Annual Growth Conference on Thursday, August 12, 2021.
  • A live webcast of the fireside chat from the Canaccord Genuity 41st Annual Growth Conference will be available on the investors section of the X4 Pharmaceuticals website at www.x4pharma.com .
  • After the live webcast, the event will remain archived on the X4 Pharmaceuticals website for approximately 90 days.
  • The companys lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy.

REPAY to Attend Canaccord Genuity 41st Annual Growth Conference on August 12, 2021

Retrieved on: 
Wednesday, August 4, 2021
Professional Services, Technology, Other Professional Services, Other Technology, Finance, Software, Genuity, Level 3 Communications, Companies, Finance, Economic history

Repay Holdings Corporation (NASDAQ: RPAY) (REPAY or the Company), a leading provider of vertically-integrated payment solutions, today announced that the Company will virtually participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021.

Key Points: 
  • Repay Holdings Corporation (NASDAQ: RPAY) (REPAY or the Company), a leading provider of vertically-integrated payment solutions, today announced that the Company will virtually participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021.
  • The presentation will be webcast live from the Company's investor relations website at https://investors.repay.com/ under the Events section.
  • An archive of the webcast will be available at the same location on the website for 90 days.
  • REPAY provides integrated payment processing solutions to verticals that have specific transaction processing needs.

Sage Therapeutics to Present at Upcoming August Investor Conferences

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, Pharmaceutical, Health, Other Health, Life sciences, Biotechnology, Articles, Pharmaceutical industry, Genuity, Biopharmaceutical

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will present at the following upcoming investor conferences in August:

Key Points: 
  • Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will present at the following upcoming investor conferences in August:
    2021 Wedbush PacGrow Healthcare Virtual Conference: Barry Greene, Chief Executive Officer of Sage Therapeutics, will be a featured speaker on the panel, The Brains of the Operation - Novel Approaches in Neuro, on Tuesday, August 10, 2021 at 12:00 p.m.
  • Canaccord Genuity 41st Annual Growth Conference: fireside chat on Wednesday, August 11, 2021 at 8:00 a.m.
  • A live webcast of each event can be accessed on the investor page of Sages website at investor.sagerx.com .
  • Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain.

Homology Medicines to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, August 4, 2021
Genuity, Companies, Finance, Service companies

BEDFORD, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today participation in fireside chats at the following virtual conferences:

Key Points: 
  • BEDFORD, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today participation in fireside chats at the following virtual conferences:
    BTIG Virtual Biotechnology Conference: August 9 at 1:30 p.m.
  • ET
    Canaccord Genuity 41st Annual Growth Conference: August 11 at 9:00 a.m.
  • Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare diseases by targeting the underlying cause of the disease.
  • Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a focus on rare diseases and believes that its data, internal manufacturing capabilities and broad intellectual property position the Company as a leader in genetic medicines.

Neoleukin Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference

Retrieved on: 
Wednesday, August 4, 2021
Life sciences, Biotechnology, Biology, Genuity, Protein design, Biopharmaceutical, De novo

SEATTLE, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., Neoleukin (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the virtual Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11, 2021 at 8:00 a.m. Eastern Time.

Key Points: 
  • SEATTLE, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., Neoleukin (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the virtual Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11, 2021 at 8:00 a.m. Eastern Time.
  • An archived replay will also be available on the company website for at least 30 days following the event.
  • Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology.
  • Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.

Akouos to Present at Upcoming August Virtual Investor Conferences

Retrieved on: 
Wednesday, August 4, 2021
Otorhinolaryngology, Branches of biology, Occupational safety and health, Otology, Canaccord Genuity, Genuity, Hearing loss, Neurotology

BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (Akouos) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will present at two upcoming virtual investor conferences in August:

Key Points: 
  • BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (Akouos) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will present at two upcoming virtual investor conferences in August:
    BTIG Biotechnology Conference.
  • Fireside chat on Tuesday, August 10 at 2:30 p.m. EDT
    Canaccord Genuity 41st Annual Growth Conference.
  • Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide.
  • Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.

CloudMD to Present at the Canaccord Genuity Growth Conference

Retrieved on: 
Wednesday, August 4, 2021
Canaccord Genuity, Genuity, Service companies

VANCOUVER, British Columbia, Aug. 04, 2021 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the Company or CloudMD), a healthcare technology company revolutionizing the delivery of care, is pleased to announce that it will be participating in the Canaccord Genuity 41st Annual Growth Conference from August 10 to 12, 2021.

Key Points: 
  • VANCOUVER, British Columbia, Aug. 04, 2021 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the Company or CloudMD), a healthcare technology company revolutionizing the delivery of care, is pleased to announce that it will be participating in the Canaccord Genuity 41st Annual Growth Conference from August 10 to 12, 2021.
  • Dr. Essam Hamza, Chief Executive Officer, will be presenting the Company on Wednesday, August 11th at 5:00pm ET (2:00pm PT) in Track 12.
  • To register or to set up a meeting, please contact your Canaccord representative directly.
  • CloudMD is digitizing the delivery of healthcare by providing a patient-centric approach, with an emphasis on continuity of care.